FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer

The tumor promoting or counteracting effects of the immune response to cancer development are thought to be mediated to some extent by the infiltration of regulatory T cells (Tregs). In the present study we evaluated the prevalence of Treg populations in stromal and epithelial compartments of normal, post atrophic hyperplasia (PAH), prostatic intraepithelial neoplasia (PIN), and tumor lesions in men with and without prostate cancer.

[1]  S. Sakaguchi,et al.  Regulatory T cells in cancer immunotherapy , 2016, Cell Research.

[2]  Holger Moch,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. , 2016, European urology.

[3]  R. Kaaks,et al.  Treg-Mediated Immune Tolerance and the Risk of Solid Cancers: Findings From EPIC-Heidelberg. , 2015, Journal of the National Cancer Institute.

[4]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[5]  M. Iversen,et al.  The number of regulatory T cells in transbronchial lung allograft biopsies is related to FoxP3 mRNA levels in bronchoalveolar lavage fluid and to the degree of acute cellular rejection. , 2013, Transplant immunology.

[6]  G. Sauter,et al.  High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. , 2013, European journal of cancer.

[7]  Jennifer R. Rider,et al.  CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3+ regulatory T cells with respect to lethal prostate cancer , 2013, Modern Pathology.

[8]  Jennifer R. Rider,et al.  Inflammation, Focal Atrophic Lesions, and Prostatic Intraepithelial Neoplasia with Respect to Risk of Lethal Prostate Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[9]  D. Tran,et al.  T regulatory cells in cancer: recent advances and therapeutic potential , 2010, Expert opinion on biological therapy.

[10]  S. Sakaguchi,et al.  Regulatory T cells in tumor immunity , 2010, International journal of cancer.

[11]  G. Parmiani,et al.  LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites , 2010, The Journal of Immunology.

[12]  E. Compérat,et al.  Distribution of Foxp3‐, CD4‐ and CD8‐positive lymphocytic cells in benign and malignant prostate tissue , 2010, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[13]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[14]  C. Stief,et al.  Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. , 2009, European journal of cancer.

[15]  W. Isaacs,et al.  Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing , 2008, Clinical Cancer Research.

[16]  S. Fox,et al.  The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia‐inducible factor (HIF)‐2α but not HIF‐1α , 2007, The Prostate.

[17]  A. Banham,et al.  CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients1 , 2006, The Journal of Immunology.

[18]  P. Pisa,et al.  Tumor escape mechanisms in prostate cancer , 2006, Cancer Immunology, Immunotherapy.

[19]  Ximing J. Yang,et al.  A Working Group Classification of Focal Prostate Atrophy Lesions , 2006, The American journal of surgical pathology.

[20]  E. Gilboa,et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.

[21]  C. June,et al.  Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma , 2005, Cancer biology & therapy.

[22]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[23]  Theodore L DeWeese,et al.  Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment , 2004, Journal of cellular biochemistry.

[24]  S. Rosenberg,et al.  CD4+CD25+ Suppressor Lymphocytes in the Circulation of Patients Immunized Against Melanoma Antigens , 2003, Journal of immunotherapy.

[25]  R. Shah,et al.  Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? , 2001, The American journal of pathology.

[26]  J. Epstein,et al.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. , 1999, The American journal of pathology.

[27]  M. Kattan,et al.  Postatrophic hyperplasia of the prostate: lack of association with prostate cancer. , 1999, The American journal of surgical pathology.

[28]  J. Epstein,et al.  Histology and cellular kinetics of prostatic atrophy. , 1998, The American journal of surgical pathology.